Acute and long-term effects of nitrendipine on resting and exercise hemodynamics in essential hypertension. 1984

M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry

The hemodynamic effects of nitrendipine have been studied at rest and during exercise in eight patients with mild to moderate essential hypertension. Acutely, nitrendipine (20 mg) induced at rest a decrease in arterial blood pressure (from 194/100 to 151/78 mm Hg) and an increase in heart rate (from 81 to 101 beats/min); the cardiac output was unchanged and the systemic vascular resistances fell by 30%. Similar changes were observed during exercise, i.e., a decrease in arterial blood pressure (from 245/106 to 204/87 mm Hg) and in systemic vascular resistances (-25%) with an increase in heart rate (from 133 to 142 beats/min). After chronic treatment during 55 days (average daily dose was 46 mg), the hypotensive effects of nitrendipine were similar, although less marked, both at rest and during exercise; the tachycardia noted after acute intake disappeared after chronic therapy. The addition of atenolol (100 mg) at the end of the chronic study in six patients further reduced arterial blood pressure at rest (138/80 mm Hg) and during exercise (180/91 mm Hg); the heart rate decreased to 60 beats/min at rest and 94 beats/min during exercise. These data show that nitrendipine is a potent antihypertensive agent that induces an important fall in the systemic vascular resistances both at rest and during exercise; during chronic therapy, these antihypertensive effects were maintained while the reflex tachycardia disappeared. The addition of atenolol during chronic therapy contributed to the normalization of the resting and exercise arterial blood pressures in nearly all patients.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D009568 Nitrendipine A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. Balminil,Bay e 5009,Bayotensin,Baypresol,Baypress,Gericin,Jutapress,Nidrel,Niprina,Nitre AbZ,Nitre-Puren,Nitregamma,Nitren 1A Pharma,Nitren Lich,Nitren acis,Nitrend KSK,Nitrendepat,Nitrendi Biochemie,Nitrendidoc,Nitrendimerck,Nitrendipin AL,Nitrendipin Apogepha,Nitrendipin Atid,Nitrendipin Basics,Nitrendipin Heumann,Nitrendipin Jenapharm,Nitrendipin Lindo,Nitrendipin Stada,Nitrendipin beta,Nitrendipin-ratiopharm,Nitrendipino Bayvit,Nitrendipino Ratiopharm,Nitrensal,Nitrepress,Tensogradal,Trendinol,Vastensium,nitrendipin von ct,nitrendipin-corax,Nitre Puren,NitrePuren,Nitrendipin ratiopharm,Nitrendipinratiopharm,nitrendipin corax,nitrendipincorax
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002302 Cardiac Output The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat). Cardiac Outputs,Output, Cardiac,Outputs, Cardiac
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D005260 Female Females

Related Publications

M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
December 1981, Circulation,
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
February 1990, Deutsche medizinische Wochenschrift (1946),
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
December 1988, Fortschritte der Medizin,
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
January 1988, Clinical therapeutics,
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
January 1988, Journal of cardiovascular pharmacology,
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
January 1984, Journal of cardiovascular pharmacology,
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
December 1982, Kokyu to junkan. Respiration & circulation,
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
January 1991, Journal of cardiovascular pharmacology,
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
December 1989, Cardiovascular drugs and therapy,
M E Nannan, and J A Melin, and R J Vanbutsele, and F Lavenne, and J M Detry
April 1993, Journal of clinical pharmacology,
Copied contents to your clipboard!